Glutamatergic drugs for schizophrenia: a systematic review and meta-analysis
- 1 January 2005
- journal article
- research article
- Published by Elsevier in Schizophrenia Research
- Vol. 72 (2-3) , 225-234
- https://doi.org/10.1016/j.schres.2004.05.005
Abstract
No abstract availableKeywords
This publication has 48 references indexed in Scilit:
- Effects of d-cycloserine on negative symptoms in schizophreniaSchizophrenia Research, 2004
- Effect sizes in cumulative meta-analyses of mental health randomized trials evolved over timeJournal of Clinical Epidemiology, 2004
- Receptor mechanisms and circuitry underlying NMDA antagonist neurotoxicityMolecular Psychiatry, 2002
- The Emerging Role of Glutamate in the Pathophysiology and Treatment of SchizophreniaAmerican Journal of Psychiatry, 2001
- Systematic reviews in health care: Investigating and dealing with publication and other biases in meta-analysisBMJ, 2001
- Double-blind, placebo-controlled, cross-over trial of clozapine plus glycine in refractory schizophrenia: Negative resultsEuropean Neuropsychopharmacology, 2001
- Network interactions in schizophrenia — therapeutic implicationsBrain Research Reviews, 2000
- Piracetam in the treatment of schizophrenia: implications for the glutamate hypothesis of schizophreniaJournal of Clinical Pharmacy & Therapeutics, 1999
- Effects of Piracetam on N-Methyl-D-Aspartate Receptor Properties in the Aged Mouse BrainPharmacology, 1993
- Meta-analysis in clinical trialsControlled Clinical Trials, 1986